|
1.
|
|
13 p, 1009.5 KB |
Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days after Allogeneic Hematopoietic Stem Cell Transplant
/
Dandoy, C.E. (Cincinnati Children's Hospital Medical Center) ;
Kim, S. (Medical College of Wisconsin) ;
Chen, M. (Medical College of Wisconsin) ;
Ahn, Kwang Woo (Medical College of Wisconsin) ;
Ardura, M.I. (Nationwide Children's Hospital) ;
Brown, V. (Penn State Hershey Children's Hospital) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Diaz, M.A. (Hospital Infantil Universitario Niño Jesús (Madrid)) ;
Dvorak, C. (University of California) ;
Farhadfar, N. (University of Florida) ;
Flagg, A. (Yale New Haven Hospital) ;
Ganguly, S. (University of Kansas Health System) ;
Hale, G.A. (Johns Hopkins All Children's Hospital) ;
Hashmi, S.K. (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Hematti, Peiman (University of Wisconsin) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Nishihori, T. (Lee Moffitt Cancer Center and Research Institute) ;
Nusrat, R. (Rutgers Robert Wood Johnson Medical School) ;
Olsson, R.F. (Uppsala University) ;
Rotz, S.J. (Cleveland Clinic Children's Hospital) ;
Sung, A.D. (Duke University School of Medicine) ;
Perales, M.A. (Memorial Sloan Kettering Cancer Center) ;
Lindemans, C.A. (Princess Maxima Center for Pediatric Oncology) ;
Komanduri, K.V. (University of Miami) ;
Riches, M.L. (University of North Carolina at Chapel Hill) ;
Universitat Autònoma de Barcelona
Importance: Patients undergoing hematopoietic stem cell transplant (HSCT) are at risk for bloodstream infection (BSI) secondary to translocation of bacteria through the injured mucosa, termed mucosal barrier injury-laboratory confirmed bloodstream infection (MBI-LCBI), in addition to BSI secondary to indwelling catheters and infection at other sites (BSI-other). [...]
2020 -  10.1001/jamanetworkopen.2019.18668
JAMA network open, Vol. 3 Núm. 1 (2020) , p. e1918668
|
|
|
2.
|
|
8 p, 440.5 KB |
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : A Report on Behalf of the American Society for Transplantation and Cellular Therapy
/
Kharfan-Dabaja, Mohamed A. (Mayo Clinic. Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program) ;
Kumar, Ambuj (Program for Comparative Effectiveness Research. Morsani College of Medicine. University of South Florida) ;
Ayala, Ernesto (Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program. Mayo Clinic) ;
Aljurf, Mahmoud (Department of Adult Hematology and Stem Cell Transplantation. King Faisal Specialist Hospital and Research Centre) ;
Nishihori, Taiga (Department of Blood and Marrow Transplantation and Cellular Immunotherapy. Moffitt Cancer Center) ;
Marsh, Rebecca (Cincinnati Children's Hospital Medical Center) ;
Burroughs, Laura M. (Fred Hutchinson Cancer Research Center) ;
Majhail, Navneet (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Al-Homsi, Ahmad Samer (NYU Langone Health) ;
Al-Kadhimi, Zaid S. (Division of Oncology and Hematology. Department of Internal Medicine. University of Nebraska Medical Center) ;
Bar, Merav (Fred Hutchinson Cancer Research Center) ;
Bertaina, Alice (Division of Stem Cell Transplant and Regenerative Medicine. Department of Pediatrics. Stanford University) ;
Boelens, Jaap Jan (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Champlin, Richard (Department of Stem Cell Transplantation and Cellular Therapy. The University of Texas MD Anderson Cancer Center) ;
Chaudhury, Sonali (Ann and Robert H. Lurie Children's Hospital of Chicago) ;
DeFilipp, Zachariah (Massachusetts General Hospital (Boston)) ;
Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ;
El-Jawahri, Areej (Massachusetts General Hospital (Boston)) ;
Fanning, Suzanne (Blood and Marrow Transplant Program. University of South Carolina School of Medicine) ;
Fraint, Ellen (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Gergis, Usama (Bone Marrow Transplant and Immune Cellular Therapy. Thomas Jefferson University Hospital) ;
Giralt, Sergio (Department of Medicine. Division of Hematologic Malignancies. Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Hamilton, Betty K. (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Hashmi, Shahrukh K (Department of Medicine. Sheikh Shakhbout Medical City) ;
Horn, Biljana (Department of Pediatrics. Division of Hematology/Oncology. University of Florida. UF Health Shands Children's Hospital) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Jacobsohn, David A. (Children's National Medical Center) ;
Jain, Tania (Johns Hopkins University School of Medicine) ;
Johnston, Laura (Stanford University School of Medicine) ;
Kanate, Abraham S. (West Virginia University) ;
Kansagra, Ankit (UT Southwestern Medical Center) ;
Kassim, Adetola (Vanderbilt University Medical Center) ;
Kean, Leslie S. (Boston Children's Hospital. Dana-Farber Cancer Institute) ;
Kitko, Carrie L. (Vanderbilt University Medical Center) ;
Knight-Perry, Jessica (University of Colorado School of Medicine) ;
Kurtzberg, Joanne (Duke University School of Medicine) ;
Liu, Hien (Moffitt Cancer Center) ;
MacMillan, Margaret L (University of Minnesota Medical School) ;
Mahmoudjafari, Zahra (University of Kansas Cancer Center) ;
Mielcarek, Marco (Fred Hutchinson Cancer Research Center) ;
Mohty, Mohamad (Sorbonne Université. INSERM. Centre de Recherche Saint-Antoine and Hôpital Saint-Antoine. Service d'Hématologie Clinique et Thérapie Cellulaire) ;
Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ;
Nemecek, Eneida (Oregon Health & Science University) ;
Olson, Timothy S. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Perales, Miguel Angel (Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Prockop, Susan E. (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Pulsipher, Michael A. (Children's Hospital Los Angeles Cancer and Blood Disease Institute. USC Keck School of Medicine) ;
Pusic, Iskra (Washington University School of Medicine) ;
Riches, Marcie L. (University of North Carolina at Chapel Hill) ;
Rodriguez, Cesar (Wake Forest University School of Medicine) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Rondon, Gabriela (The University of Texas MD Anderson Cancer Center) ;
Saad, Ayman (The Ohio State University. Division of Hematology) ;
Shah, Nina (University of California San Francisco. Department of Medicine) ;
Shaw, Peter J. (The Children's Hospital at Westmead) ;
Shenoy, Shalini (Washington University School of Medicine) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Talano, Julie (Children's Hospital of Wisconsin) ;
Verneris, Michael R. (University of Colorado School of Medicine) ;
Veys, Paul (University College London. Great Ormond Street Hospital.) ;
Wagner, John E. (University of Minnesota Medical School) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Carpenter, Paul A. (Fred Hutchinson Cancer Research Center) ;
Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of the procedure. [...]
2021 - 10.1016/j.jtct.2021.04.007
Transplantation and Cellular Therapy, Vol. 27 Núm. 8 (august 2021) , p. 642-649
|
|
|
3.
|
|
13 p, 850.9 KB |
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
/
Chhabra, Saurabh (Medical College of Wisconsin) ;
Liu, Ying (Medical College of Wisconsin) ;
Hemmer, Michael T. (Medical College of Wisconsin) ;
Costa, Luciano (University of Alabama at Birmingham. Department of Medicine) ;
Pidala, Joseph A. (H. Lee Moffitt Cancer Center and Research Institute) ;
Couriel, Daniel R. (Utah Blood and Marrow Transplant Program) ;
Alousi, Amin M. (University of Texas MD Anderson Cancer Center) ;
Majhail, Navneet S. (Cleveland Clinic Taussig Cancer Institute) ;
Stuart, Robert K. (Medical University of South Carolina) ;
Kim, Dennis (Princess Margaret Cancer Center) ;
Ringden, Olle (Karolinska Institutet (Estocolm, Suècia). Division of Therapeutic Immunology) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Saad, Ayman (University of Alabama at Birmingham) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Cooper, Brenda (University Hospitals Case Medical Center. Department of Medicine-Hematology and Oncology) ;
Marks, David I. (University Hospitals Bristol NHS Trust) ;
Socie, Gerard (Hôpital Saint Louis. Department of Hematology) ;
Schouten, Harry C. (Academische Ziekenhuis. Department of Hematology) ;
Schoemans, Helene (University Hospitals Leuven (Bèlgica)) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Yared, Jean (University of Maryland. Greenebaum Cancer Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes. Department of Hematology) ;
Wagner, John (Thomas Jefferson University. Department of Medical Oncology) ;
Antin, Joseph H. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Verdonck, Leo F. (Isala Clinic. Departmentt of Hematology/Oncology) ;
Lehmann, Leslie (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
MacMillan, Margaret L. (University of Minnesota Blood and Marrow Transplant Program) ;
Litzow, Mark R. (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Solh, Melhem M. (Northside Hospital. Blood and Marrow Transplant Group of Georgia) ;
Qayed, Muna (Emory University School of Medicine. Department of Pediatrics) ;
Hematti, Peiman (University of Wisconsin) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Vij, Ravi (Washington University School of Medicine. Division of Hematology and Oncology) ;
Hayashi, Robert J. (Washington University School of Medicine in St. Louis. Division of Pediatric Hematology/Oncology) ;
Gale, Robert Peter (Imperial College London. Hematology Research Centre) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Seo, Sachiko (National Cancer Research Center East) ;
Hashmi, Shahrukh K (Mayo Clinic Rochester. Division of Hematology and Transplant Center) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Teshima, Takanori (Kyushu University Hospital) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center. Department of Medical Oncology) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Spellman, Stephen R. (Center for International Blood and Marrow Transplant Research) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Hamilton, Betty K. (Cleveland Clinic Taussig Cancer Institute) ;
Universitat Autònoma de Barcelona
The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. [...]
2019 - 10.1016/j.bbmt.2018.08.018
Biology of blood and marrow transplantation, Vol. 25 Núm. 1 (january 2019) , p. 73-85
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
